Skip to content
Head to head

Zenas BioPharma vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ZBIO · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ZBIO -33.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ZBIOVRTX
Snapshot
Sector--Biotechnology
Last price23.85515.02
Change today-4.75%-1.08%
1-year return-31.5%+22.0%
Market cap$1.62B$130.58B
52-week range13.50 – 44.60412.27 – 568.67
Valuation
P/E (TTM)-2.3733.14
P/E percentile, own 5-yr range65th99th
P/B7.626.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-8.4415.32
Net profit (TTM)$-572.38M$3.88B
Revenue (TTM)$11.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-2747.5%33.1%
Net margin-4925.5%30.7%
Free cash flow (TTM)$-272.83M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership119.9%96.8%
Insider activity (12mo)49 buy / 0 sell28 buy / 22 sell
Short interest (% of float)17.4%1.9%
Analyst consensus67% buy / 33% hold (3)95% buy / 5% hold (21)
Analyst price target$41 (+73%)$624 (+21%)
StockVane view
StockVane Quant RatingE (11)C (68)
Company
Employees1676,400
Founded20191989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.